JP2005506995A - 非神経障害性疼痛を処置するための方法 - Google Patents
非神経障害性疼痛を処置するための方法 Download PDFInfo
- Publication number
- JP2005506995A JP2005506995A JP2003537569A JP2003537569A JP2005506995A JP 2005506995 A JP2005506995 A JP 2005506995A JP 2003537569 A JP2003537569 A JP 2003537569A JP 2003537569 A JP2003537569 A JP 2003537569A JP 2005506995 A JP2005506995 A JP 2005506995A
- Authority
- JP
- Japan
- Prior art keywords
- pain
- lidocaine
- pain associated
- patch
- neuropathic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 44
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 29
- 208000002193 Pain Diseases 0.000 claims abstract description 116
- 230000036407 pain Effects 0.000 claims abstract description 116
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960004194 lidocaine Drugs 0.000 claims abstract description 44
- 230000006378 damage Effects 0.000 claims abstract description 23
- 208000014674 injury Diseases 0.000 claims abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 12
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 12
- 208000034656 Contusions Diseases 0.000 claims abstract description 11
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 208000001294 Nociceptive Pain Diseases 0.000 claims abstract description 7
- 230000036592 analgesia Effects 0.000 claims abstract description 6
- 206010003246 arthritis Diseases 0.000 claims abstract description 6
- 230000009519 contusion Effects 0.000 claims abstract description 6
- 208000004550 Postoperative Pain Diseases 0.000 claims abstract description 5
- 208000026137 Soft tissue injury Diseases 0.000 claims abstract description 5
- 208000010040 Sprains and Strains Diseases 0.000 claims abstract description 5
- 206010006811 Bursitis Diseases 0.000 claims abstract description 4
- 210000003041 ligament Anatomy 0.000 claims abstract description 4
- 210000002435 tendon Anatomy 0.000 claims abstract description 4
- 230000003252 repetitive effect Effects 0.000 claims abstract description 3
- 206010040030 Sensory loss Diseases 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 206010024453 Ligament sprain Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 206010008685 Chondritis Diseases 0.000 claims 1
- 208000034526 bruise Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000025978 Athletic injury Diseases 0.000 abstract description 2
- 206010041738 Sports injury Diseases 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 208000029549 Muscle injury Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 abstract 1
- 210000004262 dental pulp cavity Anatomy 0.000 abstract 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 description 15
- 210000005036 nerve Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 108010052164 Sodium Channels Proteins 0.000 description 11
- 102000018674 Sodium Channels Human genes 0.000 description 11
- 210000000929 nociceptor Anatomy 0.000 description 9
- 108091008700 nociceptors Proteins 0.000 description 9
- 206010033799 Paralysis Diseases 0.000 description 8
- 229940035676 analgesics Drugs 0.000 description 6
- 229940035674 anesthetics Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 239000003193 general anesthetic agent Substances 0.000 description 6
- 230000003040 nociceptive effect Effects 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 229940005483 opioid analgesics Drugs 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 239000003195 sodium channel blocking agent Substances 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000002240 Tennis Elbow Diseases 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 230000002917 arthritic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940060977 lidoderm Drugs 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000004341 tarsal joint Anatomy 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001361 achilles tendon Anatomy 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- -1 dubicaine Chemical compound 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 230000037324 pain perception Effects 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010049140 Endorphins Proteins 0.000 description 2
- 102000009025 Endorphins Human genes 0.000 description 2
- 108010092674 Enkephalins Proteins 0.000 description 2
- 201000011275 Epicondylitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 229940089973 Sodium channel antagonist Drugs 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229940123268 Sodium antagonist Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940005553 analgesics and anesthetics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/045,341 US20030124174A1 (en) | 2001-10-25 | 2001-10-25 | Method for treating non-neuropathic pain |
| PCT/US2002/034077 WO2003035000A2 (en) | 2001-10-25 | 2002-10-23 | Method for treating non-neuropathic pain |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009286980A Division JP2010065059A (ja) | 2001-10-25 | 2009-12-17 | 非神経障害性疼痛を処置するための方法 |
| JP2010122735A Division JP2010202663A (ja) | 2001-10-25 | 2010-05-28 | 非神経障害性疼痛を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506995A true JP2005506995A (ja) | 2005-03-10 |
| JP2005506995A5 JP2005506995A5 (https=) | 2006-01-05 |
Family
ID=21937331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003537569A Withdrawn JP2005506995A (ja) | 2001-10-25 | 2002-10-23 | 非神経障害性疼痛を処置するための方法 |
| JP2009286980A Pending JP2010065059A (ja) | 2001-10-25 | 2009-12-17 | 非神経障害性疼痛を処置するための方法 |
| JP2010122735A Pending JP2010202663A (ja) | 2001-10-25 | 2010-05-28 | 非神経障害性疼痛を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009286980A Pending JP2010065059A (ja) | 2001-10-25 | 2009-12-17 | 非神経障害性疼痛を処置するための方法 |
| JP2010122735A Pending JP2010202663A (ja) | 2001-10-25 | 2010-05-28 | 非神経障害性疼痛を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20030124174A1 (https=) |
| EP (1) | EP1446087A4 (https=) |
| JP (3) | JP2005506995A (https=) |
| CN (1) | CN1571656B (https=) |
| CA (1) | CA2464067C (https=) |
| WO (1) | WO2003035000A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024530821A (ja) * | 2021-09-09 | 2024-08-23 | アンドロス ファーマシューティカルズ シーオー．，エルティディー． | 局所麻酔剤－粘土複合組成物 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
| US20030118632A1 (en) * | 2001-12-26 | 2003-06-26 | Larry Caldwell | Methods and compositions for treating carpal tunnel syndrome |
| DE10332487A1 (de) * | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| EP1696877A4 (en) * | 2003-11-13 | 2010-06-09 | Gen Hospital Corp | PROCESS FOR PAIN TREATMENT |
| US20050112183A1 (en) * | 2003-11-25 | 2005-05-26 | Galer Bradley S. | Compositions and methods for treating neuropathic sensory loss |
| US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| WO2006036936A2 (en) * | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
| JP4921739B2 (ja) * | 2005-08-10 | 2012-04-25 | 久光製薬株式会社 | 皮膚刺激を低減した貼付剤 |
| US7592458B2 (en) * | 2006-07-21 | 2009-09-22 | Wright George E | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain |
| AU2007325918B2 (en) | 2006-11-03 | 2013-10-17 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
| US8549015B2 (en) * | 2007-05-01 | 2013-10-01 | Giancarlo Barolat | Method and system for distinguishing nociceptive pain from neuropathic pain |
| CA2703872C (en) * | 2007-11-11 | 2015-11-03 | Medrx Co., Ltd. | Lidocaine tape preparation |
| US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
| US9012477B2 (en) * | 2009-01-06 | 2015-04-21 | Nuvo Research Inc. | Method of treating neuropathic pain |
| US20110086913A1 (en) * | 2009-04-01 | 2011-04-14 | Jie Zhang | Methods for treating myofascial, muscle, and/or back pain |
| US9186334B2 (en) | 2009-05-04 | 2015-11-17 | Nuvo Research Inc. | Heat assisted lidocaine and tetracaine for transdermal analgesia |
| CN102427792A (zh) * | 2009-05-04 | 2012-04-25 | 扎斯制药公司 | 治疗与神经瘤、神经卡压及其他病况相关联的疼痛的方法 |
| US20110008413A1 (en) * | 2009-07-08 | 2011-01-13 | Msk Pharma, Llc | Compositions and Methods of Topical Drug Delivery for the Treatment of Carpal Tunnel Syndrome |
| CN102834096A (zh) | 2010-01-14 | 2012-12-19 | 卢福研究公司 | 用于疼痛控制的固态成型局部麻醉制剂 |
| AU2016259348B9 (en) * | 2010-04-13 | 2018-11-29 | Relmada Therapeutics, Inc. | Dermal pharmaceutical compositions of 1-Methyl-2',6' pipecoloxylidide and method of use |
| JP5927506B2 (ja) | 2010-04-13 | 2016-06-01 | レルマダ セラピューティクス、インク． | １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法 |
| US12201676B2 (en) | 2011-03-18 | 2025-01-21 | Dr Healthcare España, S.L. | Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome |
| ES2387973B1 (es) * | 2011-03-18 | 2013-10-01 | Dr Healthcare España, S. L. | Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor. |
| ES2388395B1 (es) * | 2011-03-18 | 2013-10-01 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención de la fibromialgia o la fatiga crónica. |
| US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
| BR112013028802B1 (pt) | 2011-05-10 | 2021-10-26 | Itochu Chemical Frontier Corporation | Curativo adesivo não-aquoso |
| ES3034911T3 (en) | 2011-05-10 | 2025-08-26 | Itochu Chemical Frontier Corp | Non-aqueous patch |
| LT2823815T (lt) | 2011-09-27 | 2018-08-27 | Itochu Chemical Frontier Corporation | Nevandeninis pleistras |
| EP2822641B1 (en) * | 2012-03-08 | 2019-06-19 | SPR Therapeutics, Inc. | System for treatment of pain related to limb joint replacement surgery |
| ES2426539B1 (es) | 2012-04-18 | 2014-09-09 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) |
| CN108024979A (zh) * | 2015-08-24 | 2018-05-11 | 伊藤忠富隆达化工株式会社 | 包含利多卡因的非水性贴剂 |
| WO2017151806A1 (en) | 2016-03-01 | 2017-09-08 | Kitotech Medical, Inc. | Microstructure-based systems, apparatus, and methods for wound closure |
| WO2018160797A1 (en) * | 2017-03-01 | 2018-09-07 | Arctic Fox Biomedical, Inc. | Cryotherapies |
| WO2021168345A1 (en) * | 2020-02-19 | 2021-08-26 | Kitotech Medical, Inc. | Microstructure systems and methods for pain treatment |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7713617L (sv) * | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | Antitranspirationsmedel |
| US4460368A (en) * | 1981-10-29 | 1984-07-17 | Almedco, Inc. | Trans-dermal medication system |
| IT1177863B (it) * | 1984-07-03 | 1987-08-26 | Fidia Farmaceutici | Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche |
| US4963345A (en) * | 1988-07-18 | 1990-10-16 | Forrest Kim K | Injectable local anesthetic antidote |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| CA1338779C (en) * | 1989-03-17 | 1996-12-10 | Harry Hind | Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics |
| US5411738A (en) * | 1989-03-17 | 1995-05-02 | Hind Health Care, Inc. | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
| US5139786A (en) * | 1989-07-07 | 1992-08-18 | Ciba-Geigy Corporation | Topical formulations |
| US5447947A (en) * | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
| JP3004769B2 (ja) * | 1990-05-30 | 2000-01-31 | フェリック株式会社 | 温熱治療用構造物 |
| KR100198044B1 (ko) * | 1991-05-13 | 1999-06-15 | 아이 에이 호틴 | 이부프로펜 염을 포함하는 약제학적 조성물 |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| GB9212450D0 (en) * | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
| US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| WO1994000484A1 (en) * | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
| IL106484A (en) * | 1992-07-31 | 1998-08-16 | Lai John | Compositions for therapeutic and anaesthetic treatment and the use thereof |
| US5462743A (en) * | 1992-10-30 | 1995-10-31 | Medipro Sciences Limited | Substance transfer system for topical application |
| ES2160623T3 (es) * | 1992-12-31 | 2001-11-16 | Sunkyong Ind Ltd | Composiciones farmaceuticas mejoradas para la penetracion en la piel de piroxicam. |
| WO1994023748A1 (en) * | 1993-04-08 | 1994-10-27 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
| US5478566A (en) * | 1993-09-29 | 1995-12-26 | Loria; Roger M. | Stimulation of cytokine production |
| US5376662A (en) * | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
| FR2713637B1 (fr) * | 1993-12-15 | 1996-01-05 | Cird Galderma | Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| FR2713635B1 (fr) * | 1993-12-15 | 1996-01-05 | Cird Galderma | Nouveaux composés propynyl bi-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| JPH09509156A (ja) * | 1994-02-03 | 1997-09-16 | ケンブリッジ・ニューロサイエンス・インコーポレーテッド | 治療用グアニジン類 |
| US6143791A (en) * | 1994-02-03 | 2000-11-07 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
| US5536263A (en) * | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
| US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| FR2719041B1 (fr) * | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| FR2719043B1 (fr) * | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés bicycliques-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| DE4416927C1 (de) * | 1994-05-13 | 1995-08-31 | Lohmann Therapie Syst Lts | Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung |
| SE9402453D0 (sv) * | 1994-07-12 | 1994-07-12 | Astra Ab | New pharmaceutical preparation |
| US5612382A (en) * | 1994-07-15 | 1997-03-18 | Frances B. Fike | Composition for percutaneous absorption of pharmaceutically active ingredients |
| DE4426625A1 (de) * | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE69513484T2 (de) * | 1994-10-04 | 2000-03-16 | Centre International De Recherches Dermatologiques Galderma (Cird Galderma) | Neue, von Dibenzofuran abgeleitete Verbindungen und pharmazeutische und kosmetische Zusammensetzungen, die sie enthalten. |
| JP3908795B2 (ja) * | 1994-11-29 | 2007-04-25 | 久光製薬株式会社 | ケトチフェン含有経皮投与製剤 |
| US5807568A (en) * | 1994-12-27 | 1998-09-15 | Mcneil-Ppc, Inc. | Enhanced delivery of topical compositions containing flurbiprofen |
| AUPN104895A0 (en) * | 1995-02-10 | 1995-03-09 | Lai, John | Methods of and preparations for the treatment of ailments and disorders |
| FR2730995B1 (fr) * | 1995-02-23 | 1997-04-04 | Cird Galderma | Composes bi-aromatiques derives d'amide, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
| US6166085A (en) * | 1995-04-14 | 2000-12-26 | The Regents Of The University Of California | Method of producing analgesia |
| US5849737A (en) * | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
| US5948389A (en) * | 1995-06-07 | 1999-09-07 | El Khoury & Stein, Ltd. | Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| US5795864A (en) * | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
| DE19526031A1 (de) * | 1995-07-17 | 1997-01-23 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Rückenschmerz und Muskelverspannung |
| US5667799A (en) * | 1995-10-30 | 1997-09-16 | Caldwell; Larry J. | Method for treating headache pain with topical local anesthetic compositions |
| US6248788B1 (en) * | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
| US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| US5702720A (en) * | 1995-12-22 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
| ES2230571T3 (es) * | 1995-12-28 | 2005-05-01 | Mitsubishi Pharma Corporation | `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria. |
| US5688830A (en) * | 1996-01-25 | 1997-11-18 | Syntex (U.S.A.) Inc. | Treatment of neuropathic pain |
| US5869533A (en) * | 1996-04-23 | 1999-02-09 | Holt; Stephen D. | Non-irritating capsaicin formulations and applicators therefor |
| US5856361A (en) * | 1996-04-23 | 1999-01-05 | Medical Merchandising, Inc. | Pain reliever and method of use |
| JPH09315964A (ja) * | 1996-05-27 | 1997-12-09 | Chinhin Boku | 肩こり・五十肩治療用貼付剤 |
| KR100213465B1 (ko) * | 1996-11-01 | 1999-08-02 | 최좌진 | 케토프로펜 패취 조성물 |
| US5709878A (en) * | 1996-08-02 | 1998-01-20 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US6245340B1 (en) * | 1996-12-03 | 2001-06-12 | Parvin Youssefyeh | Method of improving the immune response and compositions therefor |
| US5985933A (en) * | 1997-01-24 | 1999-11-16 | Celgene Corporation | Methods for treating central and peripheral nerve pain |
| US6113940A (en) * | 1997-03-03 | 2000-09-05 | Brooke; Lawrence L. | Cannabinoid patch and method for cannabis transdermal delivery |
| US5976547A (en) * | 1997-04-22 | 1999-11-02 | Niblick Pharmaceuticals, Inc. | Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery |
| US6132762A (en) * | 1997-05-05 | 2000-10-17 | Cristobal; Walter | Transcutaneous application of marijuana |
| US5935932A (en) * | 1997-06-13 | 1999-08-10 | University Technology Corporation | Bradykinin antagonists containing pentafluorophenylalanine |
| FR2764604B1 (fr) * | 1997-06-13 | 1999-09-10 | Cird Galderma | Composes bi-aromatiques relies par un radical propynylene ou allenylene et compositions pharmaceutiques et cosmetiques les contenant |
| US5885597A (en) * | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
| ES2241178T3 (es) * | 1997-10-27 | 2005-10-16 | Eli Lilly And Company | Profarmacos de ester de morlino-n-etilo de inhibidores indolicos de spla 2. |
| US5869090A (en) * | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US5900249A (en) * | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
| US6103771A (en) * | 1998-03-20 | 2000-08-15 | Caldwell Galer Incorporated | Method of treating neuroma pain |
| AR014809A1 (es) * | 1998-04-03 | 2001-03-28 | Advanced Medicine Inc | Compuestos multiligazon, composicion farmaceutica, metodo para prepara dichos compuestos y uso de dichos compuestos para preparar medicamentos |
| US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
| EP1182193A4 (en) * | 1999-04-09 | 2002-09-11 | Mochida Pharm Co Ltd | REMEDIES FOR NEUROGENIC PAIN |
| DE60022333T2 (de) * | 1999-04-09 | 2006-07-06 | Euro-Celtique S.A. | Natrium kanalblocker zusammensetzungen und deren verwendung |
| US6140327A (en) * | 1999-05-12 | 2000-10-31 | Eli Lilly And Company | Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor |
| US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| US6197823B1 (en) * | 1999-09-29 | 2001-03-06 | Medical Merchandising, Inc. | Pain reliever and method of use |
| EP1216243A1 (en) * | 1999-10-01 | 2002-06-26 | Advanced Medicine, Inc. | Quinazolinones and analogues and their use as local anesthetics |
| US6147102A (en) * | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
| US7018647B1 (en) * | 1999-12-27 | 2006-03-28 | Teikoku Seiyaku Co., Ltd | Patches for external use |
| AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
| US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20050112183A1 (en) * | 2003-11-25 | 2005-05-26 | Galer Bradley S. | Compositions and methods for treating neuropathic sensory loss |
-
2001
- 2001-10-25 US US10/045,341 patent/US20030124174A1/en not_active Abandoned
-
2002
- 2002-10-23 CA CA2464067A patent/CA2464067C/en not_active Expired - Fee Related
- 2002-10-23 JP JP2003537569A patent/JP2005506995A/ja not_active Withdrawn
- 2002-10-23 EP EP02784262A patent/EP1446087A4/en not_active Withdrawn
- 2002-10-23 CN CN028206193A patent/CN1571656B/zh not_active Expired - Fee Related
- 2002-10-23 WO PCT/US2002/034077 patent/WO2003035000A2/en not_active Ceased
-
2006
- 2006-01-20 US US11/336,001 patent/US20060147510A1/en not_active Abandoned
-
2009
- 2009-12-17 JP JP2009286980A patent/JP2010065059A/ja active Pending
-
2010
- 2010-05-28 JP JP2010122735A patent/JP2010202663A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024530821A (ja) * | 2021-09-09 | 2024-08-23 | アンドロス ファーマシューティカルズ シーオー．，エルティディー． | 局所麻酔剤－粘土複合組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010202663A (ja) | 2010-09-16 |
| JP2010065059A (ja) | 2010-03-25 |
| WO2003035000A2 (en) | 2003-05-01 |
| EP1446087A4 (en) | 2010-06-09 |
| CN1571656B (zh) | 2010-04-07 |
| CA2464067C (en) | 2011-03-22 |
| CA2464067A1 (en) | 2003-05-01 |
| EP1446087A2 (en) | 2004-08-18 |
| WO2003035000A3 (en) | 2004-05-13 |
| CN1571656A (zh) | 2005-01-26 |
| US20030124174A1 (en) | 2003-07-03 |
| US20060147510A1 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506995A (ja) | 非神経障害性疼痛を処置するための方法 | |
| CN1750839B (zh) | 类辣椒素的给药 | |
| US6239180B1 (en) | Transdermal therapeutic device and method with capsaicin and capsaicin analogs | |
| US20070059351A1 (en) | Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods | |
| JP2006514109A (ja) | カプサイシノイドの投与 | |
| US20070202155A1 (en) | Low dose no donor-containing transdermal patch | |
| WO2008027203A2 (en) | Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue | |
| WO2007143185A2 (en) | Transdermal treatment of tendinopathy using glyceryl trinitrite | |
| US20050171199A1 (en) | Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents | |
| KR20080042769A (ko) | 구역에 대한 경피 방법 및 패치 | |
| WO2007103190A2 (en) | Transdermal treatment of tendinop athy using no donor | |
| AU2020267170B2 (en) | Methods and formulations using lithium to treat gout inflammatory arthropathy and pain | |
| AU2007216595B2 (en) | Method for Treating Non-Neuropathic Pain | |
| HUP0204208A2 (hu) | Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény | |
| Martínez et al. | Generalized dermatitis due to oral ephedrine. | |
| AU2002348049A1 (en) | Method for treating non-neuropathic pain | |
| CN118055760A (zh) | 具有可调释放曲线的可植入贮库 | |
| HK1162349A (zh) | 類辣椒素的給藥 | |
| MXPA01002883A (en) | Topical pharmaceutical composition comprising a non- | |
| HK1030853B (en) | Transdermal therapeutic device with capsaicin and capsaicin analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051020 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090629 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090928 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091005 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091028 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091217 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100528 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100714 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100728 |